Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2011 3
2012 9
2013 17
2014 12
2015 7
2016 13
2017 13
2018 16
2019 16
2020 14
2021 15
2022 10
2023 11
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23999693

131 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Xu N, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1251-60. doi: 10.1007/s00280-014-2603-9. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344761 Free PMC article. Clinical Trial.
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Hurvitz SA, et al. Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23. Lancet Oncol. 2018. PMID: 29175149 Clinical Trial.
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Borin MT, Chen M, Mocci S, Rubets I, Chittenden J, Aldairy W, Stroh M. Borin MT, et al. Cancer Chemother Pharmacol. 2015 Feb;75(2):401-10. doi: 10.1007/s00280-014-2652-0. Epub 2014 Dec 27. Cancer Chemother Pharmacol. 2015. PMID: 25542267 Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Swain SM, et al. Oncologist. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448. Epub 2013 Mar 8. Oncologist. 2013. PMID: 23475636 Free PMC article. Clinical Trial.
131 results